[HTML][HTML] Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

G Zhang, DT Frederick, L Wu, Z Wei… - The Journal of …, 2016 - Am Soc Clin Investig
The Journal of clinical investigation, 2016Am Soc Clin Investig
Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated
melanoma cells are intrinsically resistant to MAPK inhibitors (MAPKi). At the systemic level,
our knowledge of how signaling pathways underlie drug resistance needs to be further
expanded. Here, we have shown that intrinsically resistant BRAF-mutated melanoma cells
with a low basal level of mitochondrial biogenesis depend on this process to survive MAPKi …
Targeting multiple components of the MAPK pathway can prolong the survival of patients with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated melanoma cells are intrinsically resistant to MAPK inhibitors (MAPKi). At the systemic level, our knowledge of how signaling pathways underlie drug resistance needs to be further expanded. Here, we have shown that intrinsically resistant BRAF-mutated melanoma cells with a low basal level of mitochondrial biogenesis depend on this process to survive MAPKi. Intrinsically resistant cells exploited an integrated stress response, exhibited an increase in mitochondrial DNA content, and required oxidative phosphorylation to meet their bioenergetic needs. We determined that intrinsically resistant cells rely on the genes encoding TFAM, which controls mitochondrial genome replication and transcription, and TRAP1, which regulates mitochondrial protein folding. Therefore, we targeted mitochondrial biogenesis with a mitochondrium-targeted, small-molecule HSP90 inhibitor (Gamitrinib), which eradicated intrinsically resistant cells and augmented the efficacy of MAPKi by inducing mitochondrial dysfunction and inhibiting tumor bioenergetics. A subset of tumor biopsies from patients with disease progression despite MAPKi treatment showed increased mitochondrial biogenesis and tumor bioenergetics. A subset of acquired drug-resistant melanoma cell lines was sensitive to Gamitrinib. Our study establishes mitochondrial biogenesis, coupled with aberrant tumor bioenergetics, as a potential therapy escape mechanism and paves the way for a rationale-based combinatorial strategy to improve the efficacy of MAPKi.
The Journal of Clinical Investigation